IndustryCompany release

Lundbeck raises 2026 revenue and EBITDA growth guidance on Vyepti and Partner Markets

H. Lundbeck A/S · Tue 10 Nov 2026

The Danish drugmaker now expects 11-12% revenue growth and 15-19% adjusted EBITDA growth at constant exchange rates, citing strong US Vyepti sales and stronger Partner Markets.

H. Lundbeck raised its full-year 2026 financial guidance on 10 November 2026. At constant exchange rates, the company now expects revenue growth of 11-12%, up from 7-9% previously.

Adjusted EBITDA growth is now forecast at 15-19%, compared with the earlier range of 8-14%. Lundbeck attributes the upgrade mainly to the continued strong US performance of Vyepti and to Partner Markets coming in stronger than expected.

The company also said it now expects research and development investment of about DKK 5.6-5.7 billion for 2026.

Lundbeck issued the announcement as inside information under the EU Market Abuse Regulation. It came ahead of the company's Q3 financial report, so the detailed quarterly figures were not part of this release.

What it means for your team

  • Market-access and commercial teams tracking Vyepti in the US may read the raised guidance as a sign of continued uptake, although the release gives no detail on drivers beyond the headline attribution.
  • Teams working with Lundbeck as a partner or licensee should note that the company cites Partner Markets as a contributor to the upgrade.
  • The stated R&D investment of about DKK 5.6-5.7 billion gives a reference point for those following the company's pipeline spending; fuller detail is expected with the Q3 report.

Company's press release: H. Lundbeck A/S ↗

Article written by VigiEye from the official source (H. Lundbeck A/S). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →